Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?

IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.